Hereditary conditions are written into the DNA of virtually every cell in your body, starting from the moment of conception. That single biological fact creates a cascade of challenges that make these conditions extraordinarily difficult to change. The DNA change isn’t sitting in one spot you can target; it’s woven into roughly 30 trillion cells, many of which have already used those genetic instructions to build tissues and organs that can’t be rebuilt after the fact.
The Mutation Is in Every Cell
There are two broad categories of genetic mutations. Somatic mutations happen after conception in individual cells and stay localized. A somatic mutation in a skin cell, for instance, only affects that skin cell and its descendants. These mutations don’t pass to your children and aren’t present body-wide.
Hereditary mutations work completely differently. They originate in a parent’s egg or sperm cell, so when those reproductive cells combine at fertilization, the altered DNA is baked into the very first cell of the embryo. As that single cell divides and copies itself to eventually form an entire human body, every new cell carries the same change. By the time you’re an adult, that mutation exists in approximately 30 trillion cells. Males average around 36 trillion cells, females around 28 trillion. There is no realistic way to open each of those cells and swap out the faulty gene for a corrected version.
This is fundamentally different from, say, an infection, where you can target a foreign organism with a drug. The problem in a hereditary condition isn’t foreign. It’s part of you, copied faithfully into every cell your body has ever made.
Many Conditions Involve More Than One Gene
Some hereditary conditions are caused by a single gene, like sickle cell disease or cystic fibrosis. These are called monogenic disorders, and they’re the simplest to understand at a genetic level. Even so, “simple” is relative. A single-gene disorder still means one broken instruction replicated across trillions of cells.
Most hereditary conditions, though, are far more complex. Many involve multiple genes working together, where the combined effect of several small DNA variations produces the condition. Heart disease risk, for example, or susceptibility to certain psychiatric conditions can involve dozens or even hundreds of genetic variants, each contributing a small piece of the overall picture. Researchers have also found that common DNA variations that are harmless on their own can modify how a disease-causing mutation actually behaves, making the condition more or less severe depending on the combination. On top of the genes themselves, factors like chemical tags on DNA (which control when genes turn on and off), protein interactions, and metabolic processes all influence the final outcome. Fixing one gene in a multi-gene condition wouldn’t necessarily fix the condition, because the other contributing variants would still be active.
Some Damage Happens Before Birth
Certain hereditary conditions don’t just carry ongoing risk. They cause structural changes during fetal development that are essentially permanent by the time a child is born. During pregnancy, there are critical windows when organs and systems are being assembled. Genetic instructions guide how neurons multiply, migrate, and connect. They shape how the heart forms its chambers, how limbs develop, and how the brain wires itself.
If a hereditary mutation disrupts these processes during a critical window, the resulting structural changes persist for life. A heart defect caused by faulty genetic instructions during the first trimester, for instance, creates a physical malformation. Even if you could somehow correct the gene after birth, the heart has already been built with the wrong blueprint. You can sometimes repair the structure surgically, but you can’t rewind development.
This extends to subtler systems too. Stress-response pathways, neurotransmitter systems, and hormonal regulation can all be shaped during fetal development by genetic and epigenetic programming. Animal studies show that disruptions during critical fetal periods can permanently alter serotonin, dopamine, and other signaling systems. These aren’t changes you can undo by editing a gene later, because the architecture is already in place.
Gene Editing Isn’t Precise Enough Yet
CRISPR, the gene-editing tool that’s generated enormous excitement since its development, works by cutting DNA at a specific location so scientists can remove, replace, or repair a genetic sequence. In theory, this could correct hereditary mutations. In practice, two major problems limit its use.
The first is off-target effects. CRISPR sometimes cuts DNA in the wrong place. If those unintended cuts land in a coding region or a regulatory stretch of DNA, they could disrupt a healthy gene, potentially causing new problems including cancer. Research evaluating CRISPR in embryos has confirmed that off-target mutations remain a real concern, particularly when edits happen in regions that control important functions.
The second problem is mosaicism. When CRISPR is applied to a developing embryo, not every cell gets edited at the same time or in the same way. Some cells end up with the correction, others don’t, and still others get unintended variations. The result is an organism with a patchwork of different genetic versions across its cells. Studies in livestock embryos have found that mosaicism rates remain stubbornly high, and breeding mosaic animals to produce offspring with a clean, uniform edit can take years. In humans, where selective breeding obviously isn’t an option, mosaicism makes it nearly impossible to guarantee a consistent correction across the body.
Where Gene Therapy Has Succeeded
Despite all of these obstacles, there has been genuine progress for a narrow set of hereditary conditions. The key insight behind current gene therapies is that you don’t always need to fix every cell. For blood disorders, you only need to fix the blood-forming stem cells.
Sickle cell disease is the clearest success story. In 2023, the FDA approved the first CRISPR-based therapy for sickle cell disease. The approach works by removing a patient’s own blood stem cells, editing them in a lab to correct the genetic defect, and then infusing them back into the body. Because blood cells are constantly regenerating from stem cells, the corrected stem cells produce healthy red blood cells going forward. Patient outcomes have been impressive, with significant reductions in disease severity.
This strategy works precisely because blood is a self-renewing system with a central source. You don’t need to reach 30 trillion cells. You need to reach the stem cells in bone marrow, and the body does the rest. But this approach doesn’t translate easily to conditions affecting the brain, the skeleton, the heart, or other tissues where cells are deeply embedded, don’t regenerate the same way, or where the damage was done during development.
Legal and Ethical Barriers to Germline Editing
Even if the technology worked perfectly, there’s another layer of restriction. The most direct way to prevent a hereditary condition would be to edit the DNA in an embryo before it develops, correcting the mutation so it never appears in any of the child’s cells. This is called heritable genome editing, because the change would pass to future generations.
No country currently allows it. A 2020 survey of 96 countries found that 70 have clear policies against heritable genome editing, and while 11 countries (including the US, UK, China, and Japan) permit some laboratory research on embryos, none endorse clinical use. The scientific community broadly agrees that the safety and efficacy questions are unresolved, and the risks of introducing permanent, heritable errors into the human gene pool are too great.
This consensus hardened after a Chinese researcher announced in 2018 that he had edited the genomes of twin embryos that were carried to term. The scientific response was swift condemnation. China subsequently amended its civil and criminal codes to explicitly prohibit implanting genetically edited embryos into humans. International scientific bodies issued statements that the technology remains too uncertain for clinical trials on heritable changes.
China’s 2024 ethical guidelines put it plainly: clinical research on heritable genome editing is “irresponsible and not allowed” until safety and effectiveness are resolved and broad social consensus exists. The US effectively blocks it through a longstanding Congressional rider that prohibits the FDA from reviewing any application involving heritable genetic modification of human embryos.
What “Not Possible” Really Means
When people say it’s not possible to change hereditary conditions, they’re describing a convergence of obstacles rather than a single barrier. The mutation is everywhere in the body, not in one accessible location. Many conditions involve complex interactions among multiple genes and environmental factors that can’t be addressed by editing a single sequence. Critical developmental windows mean some effects are locked in before birth. Current editing tools introduce too many errors and inconsistencies for safe, whole-body use. And even if the technology improved dramatically, legal frameworks around the world prohibit the one approach (editing embryos) that could theoretically address the problem at its root.
For a small number of conditions where the affected tissue is accessible and self-renewing, gene therapy is already changing lives. But for the vast majority of hereditary conditions, management and treatment of symptoms remain the realistic path, not because scientists aren’t trying, but because the biology is genuinely that complex.